1078P - Multidisciplinary Team Management in Head and Neck Cancer: the real life experience.

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancers in Adolescents and Young Adults (AYA)
Head and Neck Cancers
Presenter Jean-Baptiste Guy
Citation Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374
Authors J. Guy1, Y. Xia1, A. Vallard1, S. Espenel1, J. Trone1, J. Langrand-Escure1, A. Hamrouni1, M. Ben Mrad1, C. Rancoule1, S. Ouni1, T. Muron2, P. Fournel2, N. Magne1
  • 1Radiation Oncology, Institut de Cancérologie Lucien Neuwirth, 42270 - Saint-etienne/FR
  • 2Medical Oncology, Institut de Cancérologie Lucien Neuwirth, 42270 - Saint-etienne/FR



Multidisciplinary team (MDT) management in oncology is integrated in a legal framework in France. This practice is essential in Head and Neck cancer management with its complex and multimodal treatments. Some trials report a positive impact of MDT on overall survival of advanced head and neck cancers. The objective of this study was to report the experience of MDT management in Head and Neck Cancer in the Lucien Neuwirth Cancer Institute over the past 6 years.


Records from bi-monthly MDT meeting from 2010 to 2015 were selected for this study. Number of medical cases and type of present medical specialists were noticed. Data from MDT records were reported: clinical characteristics (performans status, weight), anatomical localisation, TNM and pathological classification, and the treatment plan decision. Impact of MDT meeting on treatment delay was also analysed.


As of December 2015, 1848 clinical cases were discussed with 1786 patients and 138 MDT meetings. Majority of patients were discussed only once in meeting, and 3% (52) patients were discussed twice. An average of 16 patient’s cases were discussed per-meeting. 1368 patients (74.1%) were presented at primo-diagnosis status and 481 (25.9%) in a recurrence status. 81% of patients were at stage III or IV. 969 (52.4%) patients had a treatment before MDT. Surgery (73.2%) was the main treatment operated before meeting. Radiation therapy delay after MDT was 9.8 days for dosimetric planification CT and 21 days for first radiation treatment session.


The percentage of presented recurrent patients is reasonable regarding epidemiologic data in head and neck location. MDT seems not delay radiation treatment occurring within 21 days after MDT. Unfortunately we underlighted a majority of patients surgically treated before MDT discussion.

Clinical trial identification

Legal entity responsible for the study

Nicolas Magné




All authors have declared no conflicts of interest.